ArticleFrontiers in pharmacology2023

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.

Tingting Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.